Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology - 1 Jul 2025

Lee Jason K, Pollard Stephen J, Liu Mark C, Schleich Florence, Pelaia Girolamo, Almonacid Carlos, Heaney Liam G, Chaudhuri Rekha, Alfonso-Cristancho Rafael, Zhang Lingjiao, Maxwell Aoife, Howarth Peter

Abstract excerpt

BACKGROUND: Some patients with severe asthma have overlapping allergic and eosinophilic phenotypes and may be eligible for anti-eosinophilic or anti-immunoglobin E (IgE) biologics. OBJECTIVE: This post hoc sub-analysis assessed real-world mepolizumab effectiveness in patients with overlapping allergic and eosinophilic phenotypes, using 1-year data from the international, prospective REALITI-A (REAL world...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Asthmatic Agents
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asthma

Share to Eosinophilia

Share to Eosinophils

Share to Immunoglobulin E

Share to Leukocyte Count

Share to Severity of Illness Index

Source

Identifiers

PMID: 39805551
DOI: 10.1016/j.anai.2025.01.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.PMID 39805551Read ↗

Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.Semantic proximity Read ↗

Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbiditiesSemantic proximity Read ↗

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotypeSemantic proximity Read ↗

The efficacy of omalizumab treatment in patients with non-atopic severe asthmaSemantic proximity Read ↗

Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.Semantic proximity Read ↗

Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Mepolizumab for eosinophilic COPD with frequent exacerbations: single-centre real-world experience in a phenotype-directed approach.Semantic proximity Read ↗

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeSemantic proximity Read ↗

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read ↗

Phenotypes and Clinical Outcomes of Omalizumab and Mepolizumab treated Difficult Asthma patientsSemantic proximity Read ↗

Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment.Semantic proximity Read ↗

Severe asthma phenotypes in patients controlled with omalizumab: A real-world study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.